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IR2P-expressing Vero cell linesThe equine herpesvirus 1 (EHV-1) negative regulatory IR2 protein (IR2P), an early 1,165-amino acid (aa)
truncated form of the 1487-aa immediate-early protein (IEP), lacks the trans-activation domain essential for
IEP activation functions but retains domains for binding DNA, TFIIB, and TBP and the nuclear localization
signal. IR2P mutants of the N-terminal region which lack either DNA-binding activity or TFIIB-binding activity
were unable to down-regulate EHV-1 promoters. In EHV-1-infected cells expressing full-length IR2P,
transcription and protein expression of viral regulatory IE, early EICP0, IR4, and UL5, and late ETIF genes were
dramatically inhibited. Viral DNA levels were reduced to 2.1% of control infected cells, but were vey weakly
affected in cells that express the N-terminal 706 residues of IR2P. These results suggest that IR2P function
requires the two N-terminal domains for binding DNA and TFIIB as well as the C-terminal residues 707 to 1116
containing the TBP-binding domain.gy and Immunology, Louisiana
s Highway, P.O. Box 33932,
4.
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Equine herpesvirus 1 (EHV-1), an alphaherpesvirus, is a major
pathogen of equines, causing respiratory disease, neurological
disorders, and spontaneous abortions in pregnant mares (Allen and
Bryans, 1986; O'Callaghan and Osterrieder, 1999; O'Callaghan et al.,
1983). The EHV-1 genome comprises 78 genes that are temporally
expressed as immediate-early (IE), early, and late (Caughman et al.,
1985; Gray et al., 1987a, 1987b). The coordinated transcription of
EHV-1 genes is regulated by seven regulatory molecules: the sole IE
protein (IEP), four early proteins [IR2P, IR4P (HSV-1 ICP22 homolog),
UL5P (HSV-1 ICP27 homolog), and EICP0P (HSV-1 ICP0 homolog)], the
late ETIF protein (HSV-1 αTIF homolog), and the late IR3 RNA (Ahn et
al., 2007, 2010; Bowles et al., 1997, 2000; Caughman et al., 1985;
Harty and O'Callaghan, 1991; Holden et al., 1992, 1994, 1995; Kim and
O'Callaghan, 2001; Kim et al., 2006; Smith et al., 1992; Zhao et al.,
1995).
The sole IE gene is expressed as a spliced 6-kb transcript that
encodes the 1487-aa IE protein (Harty and O'Callaghan, 1991). IEP
activates transcription from early and some late viral promoters
(Smith et al., 1992, 1995) and is essential for viral replication (Garko-
Buczynski et al., 1998). Conversely, it down-regulates its own
promoter (Kim et al., 1995; Smith et al., 1992) and the true lateglycoprotein K (gK) promoter (Kim et al., 1999) by binding its cognate
consensus sequence ATCGT, which overlaps the transcription initia-
tion site of these two promoters. IEP possesses several domains
essential for trans-activation including: (i) an acidic trans-activation
domain (TAD; aa 3–89); (ii) a serine-rich tract (SRT; aa 181–220) that
binds to the cellular protein EAP; (iii) a nuclear localization signal
(NLS; aa 963–970); (iv) a DNA-binding domain (DBD; aa 422–597);
and (v) a TFIIB–binding domain (aa 407–757) (Albrecht et al., 2003;
Buczynski et al., 1999, 2005; Jang et al., 2001; Kim et al., 1995, 2001;
Smith et al., 1994, 1995).
The IR2 protein which is unique to EHV-1 is encoded by the IR2
gene that lies within the IE gene and is a truncated form (aa323–
1487) of the IEP (Caughman et al., 1995; Harty and O'Callaghan,
1991). Therefore, it lacks the TAD and SRT domains of the IEP but
retains binding domains for DNA, TFIIB, and TBP, and the NLS. In
transient transfection assays, the IR2P down-regulated luciferase
reporter activity that was under the control of the sole IE promoter or
early viral promoters such as EICP0, TK, IR4, and UL5 in a dose-
dependent manner (Kim et al., 2006). In comparison to the IE protein,
IR2P is expressed at a low level at the early stage of infection because
its promoter is weak (Kim et al., 2006). Therefore, IR2P may not
completely block viral gene expression in lytic infection, but instead,
may function to reduce the production of IEP and early regulatory
proteins and thereby favor the transition to the expression of late viral
proteins required for the assembly of daughter virions.
To identify IR2P residues that mediate its negative regulatory
activity, functional domains of IR2P were characterized by use of
panels of IR2P deletion and point mutants and cell lines that express
431S.K. Kim et al. / Virology 417 (2011) 430–442full-length or partial forms of IR2P. Overall, our results suggest that
the negative regulatory function of IR2P requires both the DNA-
binding and TFIIB-binding activities and that the IR2P domain(s)
necessary for inhibition of EHV-1 replication lie within C-terminal aa
707 to 1116.
Results
The Gln173 and Lys176 residues of the IR2P WLQN region are important
for its DNA-binding activity
Our previous transient transfection assays showed that the IR2P
residues 1 to 706 which contain the DBD (aa100–275), TFIIB-binding
domain (aa86–435), and NLS (aa641–648) are important for negativeA
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Fig. 1. Gln173 and Lys176 of the WLQN region are important for the DNA-binding activity as w
motif. The top diagram represents the 1165-aa IR2P which has been divided into four regions
of amino acids from the N-terminus of IR2P. The numbers refer to the number of amino acids
region of IR2P were replaced with Ser (IR2Pm1), Glu (IR2Pm2), Ile (IR2Pm3), and Glu (IR2
determined by the gel mobility shift assay. The radiolabeled probe of the IE promoter region
GST-IR2Pmutants. The position of complex formed by GST-IR2P is indicated with an arrow. (C
IR2P mutants were incubated with GST or GST-TFIIB fusion and then precipitated with glut
gels. The bands were quantitated by PhosphorImager analysis. Marker lane: The numbers on
IR2P mutants was determined by Western blot analysis. L-M cells were transfected with 1.5
after transfection, and then IR2P was detected with an anti-IEP polyclonal antibody (pAb)
Measurement of relative ﬁreﬂy luciferase signal (E) and mRNA level (F). L-M cells were cotr
plasmids (control vector pSVSPORT, pSVIR2, and mutant plasmids). Reporter plasmid pICP2
transfection efﬁciency. The ﬁreﬂy luciferase signals were normalized to the internal secrete
were measured by RT-PCR and normalized to the level for the control vector pSVSPORT1. Da
bars show standard deviations. RLU, relative luminescence units.regulatory activity (Kim et al., 2006). The WLQN region is highly
conserved within alphaherpesvirus ICP4 homologs and directly
involved in the DNA-binding interaction (Tyler et al., 1994).
Mutagenesis analysis of the WLQN region (IEPaa493–498; IR2P
aa171–176) of the IEP indicated that Gln495 (IR2P Gln173) and
Lys498 (IR2P Lys176) residues are important for the DNA-binding
activity (Kim et al., 1997). To investigate whether the DNA-binding
activity of IR2P is necessary for negative regulation, residues Trp171,
Gln173, Asn174, and Lys176 of the WLQN region were replaced with Ser
(IR2PW171S; IR2Pm1), Glu (IR2PQ173E; IR2Pm1), Ile (IR2PN174I;
IR2Pm1), and Glu (IR2PK176E; IR2Pm1), respectively (Fig. 1A). The
four IR2 mutants were conﬁrmed by DNA sequencing (data not
shown). IR2P binds to its cognate consensus sequence ATCGT of the
EHV-1 promoters (Albrecht et al., 2005; Kim et al., 1995). ToB
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) IR2P DNA-binding domainmutants interact with TFIIB. Equal amounts of radiolabeled
athione-Sepharose 4B beads. The precipitated pellets were resolved on SDS–7.5% PAGE
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OC33 (Harty and O'Callaghan, 1991). The position of IR2P is indicated with an arrow.
ansfected with 0.12 pmol of the reporter plasmid pEICP0-Luc and 0.08 pmol of effector
2-SEAP which was very weakly affected by IR2P (data not shown) was used to assess
d alkaline phosphatase (SEAP) transfection control. The ﬁreﬂy luciferase mRNA levels
ta are averages and are representative of three or more independent experiments. Error
432 S.K. Kim et al. / Virology 417 (2011) 430–442investigate whether the four IR2P mutants bind to DNA, we carried
out gel shift assays in which each IR2P mutant synthesized as a GST
fusion protein was examined for the ability to bind to radiolabeled IE
promoter DNA (Fig. 1B). GST-wild-type (wt) IR2P and four GST-IR2P
mutants were expressed and puriﬁed as described in the Material and
Methods (data not shown). GST-wt IR2P, GST-IR2Pm1, and GST-
IR2Pm3 bound to the IE promoter DNA (Fig. 1B, lanes 3, 4, and 6,
respectively). The formation of the GST-IR2P-IE promoter DNA
complex was completely blocked by addition of unlabeled excess
competitor IE promoter DNA (data not shown). In contrast, GST-
IR2Pm2 and GST-IR2Pm4 failed to bind to the IE DNA (Fig. 1B, lanes 5
and 7, respectively), indicating that the Gln173 and Lys176 residues of
the WLQN region are important for the DNA-binding activity of IR2P.
To investigate whether the four IR2P mutants interact with TFIIB,
we performed GST-pulldown assays. WT IR2P(1–1165) and four
mutants within WLQN region IR2P(1–1165)m1, IR2P(1–1165)m2,
IR2P(1–1165)m3, and IR2P(1–1165)m4 were expressed by in vitro
transcription/translation (IVTT) reactions. As expected, GST-TFIIB
precipitated wt 35S-IR2P(1–1165), which harbors the TFIIB-binding
domain (aa86–438) (Fig. 1C, lane 4), whereas GST alone did not
(Fig. 1C, lane 3). GST-TFIIBΔ125–174 which lacks the domain for
binding to IR2P (Albrecht et al., 2003) was not able to precipitate
wild-type 35S-IR2P(1-1165), indicating that TFIIB speciﬁcally interacts
with IR2P(1–1165). GST-TFIIB precipitated all of the radiolabeled 35S-
IR2P mutants (Fig. 1C, lanes 7, 10, 13, 16), whereas GST alone did not
(Fig. 1C, lanes 6, 9, 12, 15). Taken together, these results showed that
the two mutants in Gln173 or Lys176 lost their DNA-binding activity
without affecting TFIIB-binding ability.
The DNA-binding activity of the IR2P is necessary for negative regulation
The four IR2P mutants were expressed under the control of the
simian virus 40 (SV40) promoter in mouse ﬁbroblast L-M cells and
conﬁrmed by Western blot analysis (Fig. 1D). In luciferase reporter
assays, the two IR2P with mutations expressed in Trp171 (IR2Pm1)
and Asn174 (IR2Pm3) down-regulated the EICP0 promoter by 65% and
91%, respectively, of the inhibitory activity of the wild-type (wt) IR2P
(Fig. 1E, bars 3 and 5, respectively). However, the two DNA-binding
mutants IR2Pm2 (Gln173) and IR2Pm4 (Lys176) lost most of their
inhibitory activity of the EICP0 promoter (Fig. 1E, bars 4 and 6,
respectively). IR2Pm2 and IR2Pm4 veryweakly down-regulated the IE
and early UL5 promoters by only 5% to 17% of the inhibitory activity of
the wt IR2P (data not shown). Fireﬂy luciferase mRNA level was
measured by RT-PCR in L-M cells cotransfected with the luciferase
reporter and effector plasmids. Expression of wt IR2P led to a dramatic
decrease (86%) in the amount of luciferase mRNA (Fig. 1E, bar 2).
However, IR2Pm2 and IR2Pm4 reduced luciferase mRNA levels only
by 11% and 10%, respectively, as compared to that of the wt IR2P
(Fig. 1F, bars 4 and 6, respectively), indicating that the DNA-binding
activity of IR2P is necessary for its negative regulation. Taken together,
these results suggested that IR2P inhibits viral gene expression at the
transcriptional level and that TFIIB-binding activity of IR2P alone is
not sufﬁcient for its inhibitory activity.
IR2P aa 334 to 397 are important for the inhibitory activity of IR2P
To deﬁne the domains of the IR2P that mediate negative
regulation, a panel of IR2P deletion mutants was generated and
conﬁrmed by Western blot analysis (Figs. 2A and B), and used for
luciferase reporter assays (Fig. 2C). The expression of full-length IR2P
and IR2P(217–706) [IEP(539–1029)] was conﬁrmed in our previous
publications (Jang et al., 2001; Kim et al., 2006). The IR2P deletion
mutants were detected in the nuclear extracts, indicative of nuclear
localization of the proteins (Fig. 2B). In luciferase reporter assays, IR2P
(1–706) and IR2P(78–706) down-regulated the early UL5 promoter
by 39% and 44%, respectively, of the inhibitory activity of the full-length IR2P (Fig. 2C, bars 3 and 4, respectively). When the N-terminal
residues 78 to 216 of the DNA-binding domain (DBD) of IR2P were
deleted, the inhibitory activity was reduced to the level of the control
empty reporter (Fig. 2C, bar 5). The inhibitory activity of the two C-
terminal deletion mutants IR2P(78–438)-NH and IR2P(78–397)-NH
that contain the DBD, TFIIB-binding domain, NLS, and a hemagglutinin
(HA) epitope tag was slightly reduced as compared to that of IR2P
(78–706) (Fig. 2C, bars 6 and 7, respectively). IR2P(78–397) exhibited
an inhibitory activity of 40% of that full-length IR2P (Fig. 2C, bar 7)
whereas the inhibitory activity of IR2P (78–333) was reduced to only
14% of that of wild-type IR2P (Fig. 2C, bar 8), indicating that IR2P
residues 334 to 397 are important for the inhibitory activity of IR2P.
Two C-terminal deletion mutants IR2P(78–313)-NH and IR2P(78–
293)-NH that contain the DBD and but only a portion of the TFIIB-
binding domain completely lost their inhibitory activity (Fig. 2C, bars
9 and 10, respectively). Similar results were obtained with luciferase
reporters controlled by the IE, early EICP0, or IR4 promoters (data not
shown). These ﬁndings suggested that the DNA-binding activity of
IR2P alone is not sufﬁcient for its inhibitory activity.
Deletion of IR2P residues 334 to 397 impairs TFIIB-binding activity of
IR2P
Our previous results showed that the IR2P residues 85 to 435 (IEP
aa407–757) harbor a TFIIB-binding domain (Jang et al., 2001). To
investigate whether the TFIIB-binding domain of IR2P is required for
negative regulation, ﬁve IR2P deletion mutants [IR2P(78–293)-NH,
IR2P(78–313)-NH, IR2P(78–333)-NH, IR2P(78–397)-NH, and IR2P
(78–438)-NH] were expressed by IVTT reactions and used in GST-
pulldown assays (Figs. 2D and E). The GST and GST-TFIIB fusion
protein were stably expressed and puriﬁed as described previously
(Jang et al., 2001). In GST-pulldown assays, GST-TFIIB precipitated
13% of input 35S-IR2P(78–438)-NH and 12% of input 35S-IR2P(78–
397)-NH (Fig. 2E, lanes 2 and 4, respectively), and GST was not able to
bind to either of these IR2 proteins (Fig. 2E, lanes 1 and 3,
respectively). GST-TFIIBΔ125–174which lacks the domain for binding
to IR2P was not able to precipitate 35S-IR2P(78–438)-NH (data not
shown). 35S-IR2P(78–333)-NH, 35S-IR2P(78–313)-NH, and 35S-IR2P
(78–293)-NH bound weakly to GST-TFIIB as compared to that of 35S-
IR2P(78–438)-NH (Fig. 2E, lanes 6, 8, 10, respectively), indicating that
IR2P aa 334 to 397, which are required for negative regulatory
function, are important for IR2P to interact with TFIIB. Thus, these
ﬁndings and those presented above (Figs. 1 and 2) reveal that both
DNA binding and TFIIB-binding activities are important for IR2P
function.
The C-terminal residues 707 to 1165 of IR2P are important for down-
regulation of EHV-1 promoters
The results shown in Fig. 2C indicated that the C-terminal residues
707 to 1165 of the IR2 protein are important for inhibition of EHV-1
gene expression. To conﬁrm these results, C-terminal deletion
mutants of the IR2P were expressed (Fig. 3A) and examined for the
ability to down-regulate representative EHV-1 promoters fused to the
luciferase reporter (Fig. 3B). Fireﬂy luciferase mRNA level was
measured by RT-PCR in L-M cells cotransfected with luciferase
reporter and effector plasmids. Expression of IR2P led to a dramatic
decrease (89–93%) in the amount of luciferase mRNA (Fig. 3B). When
the C-terminal portion of IR2P was deleted, luciferase mRNA levels
were reduced to approximately 38% as compared to that of full-length
IR2P in the case of all three promoters (Fig. 3B). However, the protein
levels of GAPDH and actin were not changed in the presence of IR2P
(data not shown). Taken together, these results conﬁrmed that IR2P
inhibits viral gene expression at the transcriptional level and that the
C-terminus (aa 707–1116) of IR2P is required for its full inhibitory
effect on EHV-1 promoters.
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aa 100–275), the NLS, and a HA epitope tag but lacks a functional
TFIIB-binding domain down-regulated the early UL5 promoter by only
11% of the inhibitory activity of the full-length IR2P (Fig. 3C, bar 3).
The IR2P(707–1116)NH which contains residues 707 to 1116 of IR2P
down-regulated the UL5 promoter by only 22% of the IR2P's activity
(Fig. 3C, bar 4). However, the inhibitory activity of the IR2P(1–313)
(707–1116)NH inwhich the DBDwas fused to the IR2P aa 707 to 1116
was restored to 91% of the full-length IR2P's activity (Fig. 3C, bar 5),
conﬁrming that the C-terminus (aa 707–1116) of IR2P is required for
its inhibitory effect on EHV-1 promoters. In GST-pulldown assays,
GST-TFIIB bound weakly to both 35S-IR2P(1–313)-NH and 35S-IR2P
(1–313)(707–1116)-NH (see Supplementary Fig. 1) as compared to
that of 35S-IR2P(78–438)-NH (Fig. 2E), indicating that the recovery of
the inhibitory activity of the IR2P(1–313)(707–1116)-NHwas not due
to increased TFIIB-binding activity. These results suggested that TFIIB
binding is not critical for the activity of the IR2P (1–313) (707–1116)
that retains the C-terminal region.
Generation of IR2P- and IEP-expressing Vero cell lines
Findings presented in Figs. 1–3 showed that the IR2P down-
regulates the IE and early viral promoters. To investigate whetherIR2P affects EHV-1 replication and to map the inhibitory regions of
IR2P, six Vero cell lines that express full-length IR2P or portions of
IR2P were generated by use of the Invitrogen pREP4 vector system
(see Materials and Methods). The plasmid pREP4 is an episomal
mammalian expression vector that uses the Rous sarcoma virus long
terminal repeat (RSV LTR) enhancer/promoter for transcription of
recombinant genes. Use of Vero cell lines expressing IR2P or portions
of the IR2 protein overcomes the limitations of the transient
transfection approach and assures that all cells express the IR2
protein. Plasmids that harbor sequences encoding the full-length IR2P
(1–1165), IR2P(1–1116), IR2P(1–800), IR2P(1–706), IR2PΔ707/900,
IR2P(707–1116)NH, and full-length immediate-early protein(IEP1–
1487) were generated (Fig. 4A). IR2P(707–1116)NH contains the NLS
and the hemagglutinin (HA) epitope tag at its C-terminus. The validity
of the IR2 constructs was conﬁrmed by DNA sequencing (data not
shown), and expression of each IR2 construct in transfected mouse L-
M cells generated an IR2P of the expected size (Figs. 4B–D). The six
IR2P Vero cell lines IR2P, 1116, 800, 706, Δ707/900, and 707–1116,
and control vector cell line REP4 were selected, and the synthesis of
the IR2P species was conﬁrmed byWestern blot analyses (Figs. 4B and
C) and immunoﬂuorescence (IF) assays (Fig. 4E). Full-length IR2P(1–
1165) and IR2P(1–1116) were detected (Fig. 4B, lanes 5 and 7,
respectively), and faster-migrating bands (indicated by a bracket at
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or more independent experiments. (C) Luciferase reporter assays. Transient transfection assays were performed as described in Fig. 3C. RLU, relative luminescence units. Data are
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panel): IR2P [pSVIR2], 1–313 [pSVIR2(1–313)NH], and (1–313)(707–1165) [pSVIR2(1–313)(707–1165)NH] were detected with an anti-IE mAb E1.1 (12); 707–1116 [pSVIR2(707–
1116)NH] was detected with the anti-HA mAb (Sigma, St. Louis, MO). Each band was from a separate gel.
434 S.K. Kim et al. / Virology 417 (2011) 430–442the right) were observed that may be proteolytic cleavage products.
IR2P(1–800), IR2P(1–706), IR2PΔ707/900, and IR2P(707–1116)NH
were readily detected in the respective cell lines (Fig. 4C lane 4, lane 6,
lane 11, and lane 16, respectively). In the case of all six Vero cell lines,
expression of each IR2 protein species was stable for prolonged
passage of 20 or more subcultures (data not shown). The intracellular
distribution of each IR2 protein species was assessed by indirect IF
microscopy, and as expected, the full-length and the ﬁve deletion
forms of IR2P were localized to the nucleus (Fig. 4E) as all harbor the
NLS located at aa 641–648 within the full-length IR2P (Smith et al.,
1995). In IF assays of all six cell lines, more than 99% of the cells
expressed the full-length or truncated IR2P. In the Vero cell line that
expresses the IE protein, the full-length 1487-aa IEP was detected by
Western blot analysis (Fig. 4D, lane 4) and was shown to localize to
the nucleus (Fig. 4E).IR2P reduces viral gene expression
To investigate which IR2P species expressed in these cell lines alter
viral gene expression, the six IR2P- and the IEP-expressing cell lines
were infected with EHV-1 at an MOI of 5, and the expression of viral
IE, early, and late regulatory genes was monitored by RT-PCR and
Western blot analyses. In the infected full-length IR2P cell line, mRNA
levels of viral IE, early EICP0, IR4, and UL5, and late ETIF genes were
reduced to approximately 3 to 6% of the control infected REP4 cell line
(Table 1). In contrast, in the IE protein-expressing cell line, mRNA
levels of these viral genes were increased to approximately 340 to
390% of those present in the control infected cell line, indicating that
both the IE and IR2 proteins affect viral gene expression at the
transcriptional level. In the infected full-length IR2P and IR2P(1–800)
cell lines, synthesis of viral IE, early EICP0, IR4, and UL5, and late ETIF
proteins was reduced to approximately 3% and 15% of the controlinfected REP4 cell line, respectively (Fig. 5A). Synthesis of these viral
proteins in the IR2P(1–1116) cell line was also reduced to low levels
similar to those observed for the full-length IR2P cell line (data not
shown). In the case of the IR2P(1–706) cell line, the synthesis of all
ﬁve EHV-1 proteins was reduced (Fig. 5A). The amount of protein
loaded for the 706 cell linewas twice those of the control REP4 and IEP
cell lines. The full-length IR2P and the deletion forms of IR2P, IR2P(1–
800) and IR2P(1–706), were expressed at equivalent levels during
EHV-1 infection (Fig. 5A, bottom). Expression of the IE protein by the
IEP cell line was conﬁrmed as this protein was detectable at 0 hpi
(Fig. 5A). Overall, these results indicated that full-length IR2P inhibits
viral gene expression and that residues 707 to 1116 of the IR2 protein
are important for this inhibitory effect.Expression of IR2P reduces intracellular viral DNA
As shown in Fig. 5A and Table 1, ectopic expression of speciﬁc
portions of the IR2P was capable of reducing expression of all classes
of viral genes. From these results, we speculated that early regulatory
IR2P would block viral DNA replication. To address this possibility,
intracellular viral DNA levels were measured in EHV-1-infected Vero
cell lines at 24 hpi by quantitative PCR (qPCR). The intracellular viral
genomic DNA yield was signiﬁcantly reduced in the full-length IR2P-
expressing cell line to 2.1% (50-fold) as compared to that of the
infected REP4 cell line (Fig. 5B, bar 3). In the 706 cell line, viral DNA
yield was decreased by 2-fold as compared to that of the control cell
line (Fig. 5B, bar 4). However, viral DNA yield was increased by 6.1-
fold in the IEP cell line as compared to that of the control cell line
(Fig. 5B, bar 5). The 200-bp DNA fragment of pREP4 vector backbone
was ampliﬁed by qPCR in the Vero cell lines REP4, IR2P, 706, and IEP,
demonstrating that the four Vero cell lines contain pREP4 plasmid
DNA (data not shown). As expected, the virus yield was also reduced
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Table 1
The full-length IR2P cell line reduced mRNA levels of EHV-1 genes.
Vero
cell
lines
Relative mRNA level (%)a
IE EICP0 IR4 UL5 ETIF
REP4 100 100 100 100 100
IR2P 5.7±0.5 4.2±0.3 3.5±0.3 3.8±0.3 3.1±0.2
IEP N/Ab 395±37 368±39 342±25 382±27
a The cell lines expressing full-length IR2P and IEP and control cell line REP4 were
infected with EHV-1 KyA at anMOI of 5. Cells were harvested at 2 hpi for the IE, 5 hpi for
the EICP0, IR4, and UL5, and 8 hpi for the ETIF, and mRNA levels of EHV-1 genes were
measured by RT-PCR and normalized to the level for the control REP4 cell line. Data are
averages and are representative of several independent experiments.
b N/A, nonapplicable. IE mRNA is expressed from both EHV-1 and the IEP cell line.
435S.K. Kim et al. / Virology 417 (2011) 430–442by 60-fold in the full-length IR2P-expressing cell line at 24 hpi as
compared to that of the infected REP4 cell line (Fig. 5C, bar 6). The 706
cell line showed decreased virus yield of approximately 2-fold
(Fig. 5C, bar 8) as compared to that of REP4 vector control. However,
the IEP cell line showed increased virus yield of 4.8-fold (Fig. 5C, bar
10) as compared to that of the control cell line. Similar results were
obtained for assays of extracellular virus yield (Fig. 5C). Interestingly,
full-length IR2P-expressing cells were resistant to EHV-1-mediated
cell lysis at an MOI of 5, and more than 96% of the cells were viable at
72 hpi as measured by use of the CellTiter AQ One solution (see
Materials and methods) (see Supplementary Fig. 2). In contrast, more
than 95% of the cells in the REP4 control and IEP-expressing cell lines
died at 72 hpi, and cytopathic changes appeared by 24 hpi and were
characterized by shrinking and rounding of cells, followed by the
complete lysis of the monolayer. Taken together, these results
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436 S.K. Kim et al. / Virology 417 (2011) 430–442demonstrated that synthesis of the full size IR2 protein reduced the
viral DNA level and virus replication to the extent that cells were
protected from the cytopathic outcome of infection.
The C-terminal portion of IR2P is necessary for the inhibition of EHV-1
replication
Additional virus growth assays were performed with Vero cell
lines that express various portions of IR2P to map the EHV-1A EHV-1, MOI=5
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These results indicated that the C-terminal residues 707 to 1116 of the
IR2P are necessary for its protective effect against EHV-1.
To identify IR2P sequences necessary for the ability of IR2P to
inhibit EHV-1 replication, samples of the seven Vero cell lines infected
at an MOI of 5 with EHV-1 KyA were harvested at 2, 24, 48, and 72 hpi
and assayed for extracellular and intracellular virus titers by plaque
assay. The full-length IR2P cell line reduced virus yield by 100-fold at
48 hpi as compared to that of the empty vector REP4 cell line (Fig. 6B).
The IR2P(1–1116) cell line reduced virus yield by 125-fold as
compared to that of the empty vector REP4 cell line at 48 hpi
(Fig. 6B), indicating that C-terminal region aa 1117–1165 is not
necessary for the inhibitory effect. The 800 and Δ707/900 cell lines
reduced virus yield by 16-fold and 13-fold, respectively, indicating
that IR2P sequences aa 707 to 800 and aa 900 to 1116 contributed to
the inhibition of EHV-1 replication. The 706 cell line reduce virus yield
by only 3-fold (Fig. 6B). However, the 707–1165 cell line failed to
reduce virus yield (Fig. 6B). Taken together, these results suggest that
IR2P sequences aa 707 to 1116 are necessary for the inhibition of EHV-
1 replication (Fig. 7).
To assess whether the inhibition of EHV-1 replication by IR2P is
virus strain-speciﬁc, selected Vero cell lines were infected at anMOI of
5 with three different EHV-1 strains, attenuated KyA, pathogenic Ab4,
and pathogenic RacL11, and viral DNA yield was measured at 24 and
48 hpi. In the full-length IR2P-expressing cell line, the amount of EHV-
1 KyA, Ab4, and RacL11 genomic DNA was reduced to 1.3%, 6.1%, and
9.6%, respectively (data not shown) at 48 hpi as compared to the level
of these genomes in the infected control REP4 cell line These results
indicate that IR2P inhibits EHV-1 replication regardless of virus strain.Discussion
The data presented in this study revealed that the negative
regulatory function of the IR2 protein of equine herpesvirus 1 requires
both the DNA-binding and TFIIB-binding activities. The DNA-binding
and TFIIB-binding domains are overlapped within IR2P region 2
(aa94–270) which corresponds to IEP region 2 (aa416–592). EHV-1
IEP region 2 shows approximately 51% and 55% amino acid identity
with regions within both HSV-1 ICP4 and VZV ORF62, respectively(Fig. 7; Grundy et al., 1989), suggesting that residues within region 2
are important for the functions of these proteins.
Deletion of residues 314 to 435 of the TFIIB-binding domain
(aa86–435) of IR2P resulted in considerable loss of the TFIIB-binding
activity as well as complete loss of its inhibitory activity. IR2P interacts
with EHV-1 early regulatory proteins EICP0P and UL5P and abrogates
EICP0P- and UL5P-mediated trans-activation ability in a dose-
dependent manner (Kim et al., 2003, 2006). IR2P residues 314 to
435 equate with residues within the immediate-early protein that
interact with TFIIB and also overlap with domains for the IEP to
interact with regulatory UL5P (Albrecht et al., 2005) and EICP0P (Kim
et al., 2003). These facts suggest that these residues are important for
IR2P function by retarding the binding of the IEP to TFIIB and EHV-1
early regulatory proteins.
ICP4 of HSV-1 represses transcription of its own promoter and
binds viral promoter DNA cooperatively with TBP and TFIIB to form a
tripartite protein–DNA complex (Smith et al., 1993). ICP4 interacts
with TFIIB and TBP to enhance the assembly and/or stability of the
preinitiation complex (PIC) to activate transcription (Carrozza and
DeLuca, 1996; Grondin and DeLuca, 2000). Thus, a direct interaction of
IR2P with TFIIB, TBP, and other general transcription factors (GTFs)
may occur. This would block the formation of a functional PIC because
IR2P does not harbor the trans-activation domain (TAD). Our
preliminary data showed that the IEP TAD interacts with TFIIA
(Zhang and O'Callaghan, unpublished data). The TAD may induce a
conformational change in the GTFs and this could, in turn, affect the
ability of the GTFs to interact with DNA or the other GTFs. The ﬁndings
in this study revealed that the DNA-binding and TFIIB-binding
activities of IR2P are both required for its negative regulatory function.
IR2P also interacts with TBP (Kim et al., 2006). Tripartite protein–DNA
complex (IR2P-TFIIB-TBP-DNA) or protein–DNA complexes (IR2P-
TFIIB-DNA or IR2P-TBP-DNA) may explain how IR2P inhibits
transcription of viral promoters. The VZV major trans-activator IE62
activation domain (TAD) targets the humanMediator complex via the
Med25 subunit, and this interaction appears to be essential for trans-
activation by the IE62 activation domain (Yamamoto et al., 2009; Yang
et al., 2008).
The data from these studies indicated that full-length IR2P(1–
1165) and IR2P(1–1116)-expressing Vero cell lines are resistant to
EHV-1-mediated cell lysis and inhibit EHV-1 gene expression and
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1165 on EHV-1 promoters was reduced to approximately 38% of the
activity of the full-length IR2P. Unexpectedly, the IR2P(1–706) cell
line which expresses an IR2P harboring the DBD, TFIIB, and NLS
domains very weakly inhibit EHV-1 replication. The IR2P(1–800) cell
line inhibits EHV-1 replication by only 16% of the activity of the full-
length IR2P cell line (see Fig. 7). IR2P harbors more than one domain
that mediates an interaction with TBP. One of the TBP-binding
domains lies within the C-terminal residues 576 to 1165 of IR2P (Kim
et al., 2006), whichmay explain the reduced inhibitory activity of IR2P
lacking the C-terminal portion. These results suggested that the C-
terminal residues 707 to 1165 of IR2P contribute to the inhibition of
viral gene expression and may be essential for the inhibition of viral
replication during the course of a productive infection.
The C-terminal region of ICP4 of HSV-1 has also been shown to be
important in the trans-activation function of this major IE protein.
HSV-1 expressing ICP4 lacking the C-terminal region has been
described as defective for full activation of early genes, viral DNA
synthesis, and expression of late genes (Cheung, 1989). ICP4 is able to
form TBP- and RNA polymerase II (PolII)-containing complexes on the
late gC promoter, and formation of this complex required the ICP4
DNA-binding domain and its C-terminal 524 amino acids (Sampath
and DeLuca, 2008). In contrast, an ICP4 protein lacking the C-terminal
524 amino acids was able to form TBP- and RNA polymerase II (Pol II)-
containing complexes on the early TK promoter (Sampath and
DeLuca, 2008), suggesting that a region of ICP4 may differentiate
between formation of TBP- and Pol II-containing complexes on E and L
promoters. The presence of ICP4 C-terminal residues 774 to 1289
(regions 4 and 5) was important for activation in vitro and in vivo
(Carrozza and DeLuca, 1996). ICP4 interaction with TFIID involves the
TAFII250 molecule and the C-terminal region of ICP4, and this
interaction is part of the mechanism by which ICP4 activates
transcription (Carrozza and DeLuca, 1996).
The ﬁndings of this study suggested that IR2P aa 707 to 800 and aa
901 to 1116 which correspond to IEP region 4 (aa 977–1394) are
important for the inhibition of EHV-1 replication. EHV-1 IEP region 4
shows approximately 60% amino acid identity with regions within
both HSV-1 ICP4 and VZV ORF62 (Fig. 7; Grundy et al., 1989),
indicating that residues within region 4 are important for functions of
these major trans-activators. Findings from Western blot and viral
DNA yield assays of the IR2P-expressing cell lines suggest that IR2P C-
terminal residues 707 to 1116 are required for full down-regulation of
EHV-1 gene expression as well as the inhibition of viral replication.
When the DBD (IR2P aa1–313) was fused to the C-terminus (IR2P
aa707–1116), the inhibitory activity was restored in a more than an
additive fashion relative to the activity of the single DBD and C-
terminus, suggesting that the C-terminus may contain binding
domains for cellular factors required for transcription. Indeed, our
previous results showed that one TBP-binding domains lies within the
C-terminal residues 576 to 1165 of IR2P (Kim et al., 2006). Our recent
experiments showed that both IEP and IR2P interacted with Pol II (Y.
Zhang, S. K. Kim, and D. J. O'Callaghan, unpublished data), suggesting
that the C-terminal region of IR2P may interact with TBP and/or Pol II
and other transcription factors. Unexpectedly, an IR2P harboring C-
terminal residues 707 to 1116which do not contain the DBD has some
inhibitory activity (Fig. 3C, bar 4), supporting the possibility that IR2P
may inhibit EHV-1 gene expression by squelching the limited supplies
of cellular factors required for viral transcription.
The precise mechanism by which IR2P inhibits EHV-1 gene
expression and replication is unknown. In transient transfection
assays, IR2P down-regulated EHV-1 promoters (Figs. 1–3) and
abrogated trans-activation mediated by IEP and early regulatory UL5
protein (Jang et al., 2001). In this study, the levels of EHV-1 genomic
DNA, mRNA, and proteins as well as the virus yield were signiﬁcantly
reduced in the IR2P-expressing cell line. These results suggested that
IR2P inhibits viral gene expressionwhich leads to virus attenuation bydirect interference with virus replication. In luciferase reporter assays,
IR2P reduced luciferase mRNA level, demonstrating that IR2P inhibits
viral gene expression at the transcriptional level. IR2P physically
interacted with the general transcription factors TFIIB and TBP
(Albrecht et al., 2003; Jang et al., 2001; Kim et al., 2006). On the
basis of these ﬁndings, we hypothesize that IR2P functions as a
dominant-negative regulator of EHV-1 gene expression by blocking
IEP-binding to viral promoter sequences and/or by squelching the
limited supplies of TFIIB, TBP, and/or other cell factors required for
viral transcription.
IR2P may contribute to the switch from early to late gene
expression in the EHV-1 gene program. Our recent work revealed
that the IR3 RNA transcript that is antisense to a portion of the IE
mRNA negatively regulates IE gene expression (Ahn et al., 2007,
2010). Thus the IR2P and IR3 RNA are two EHV-1-unique modulators
that negatively affect the expression of the sole IE gene at the level of
transcription. In addition, our most recent studies showed that the
EHV-1 early UL4 protein down-regulates viral promoters and seems
to function by a mechanism quite different from that of IR2P (Charvat
et al., in press). Thus, EHV-1 employs the early IR2 and UL4 proteins
and the IR3 antisense transcript to modulate viral gene expression. It
is possible that these EHV-1 gene products contribute to the events of
lytic infection but also play more important roles in EHV-1 latency.
Ongoing efforts to generate and characterize EHV-1 mutant viruses
that fail to express these negative regulators should give more insight
into their importance in EHV-1 biology.
Materials and methods
Viruses and cell culture
The KyA strain of EHV-1 was propagated in suspension cultures of
L-M mouse ﬁbroblasts as previously described (O'Callaghan et al.,
1968; Perdue et al., 1974). Two pathogenic Ab4 and RacL11 strains
were propagated in equine NBL6 cells. Mouse ﬁbroblast L-M, rabbit
kidney RK-13, and Vero cells were maintained at 37 °C in complete
Eagle's Minimum Essential Medium (EMEM) supplemented with 100
U/ml of penicillin, 100 μg/ml of streptomycin, nonessential amino
acids, and 5% fetal bovine serum.
Mammalian expression and in vitro transcription/translation plasmids
Plasmids were constructed and maintained in Escherichia coli (E.
coli) HB101 or JM109 by standard methods (Sambrook et al., 1989).
Plasmids pSVIE, pSVIR2, pSVIR2(217–706) [pSVIE(539–1029)] have
been described previously (Kim et al., 2003, 2006; Smith et al., 1992,
1995). Expression vector pSVSPORT1 (GIBCO-BRL, Grand Island, NY)
can be used for both mammalian expression and in vitro transcrip-
tion/translation. To generate plasmid pSVIR2(1–706), pSVIR2 was
digested with KpnI and EcoRI, blunted with Klenow fragment, a
HindIII linker (5′-ccaagcttgg-3′) was inserted, and the plasmid was
designated pSVIR2-H. Plasmid pSVIR2-H was digested with XbaI,
blunted with Klenow fragment, a KpnI linker (5′-gggtaccc-3′) was
inserted, and the plasmid was designated pSVIR2-KH. The 3.9-kb
KpnI–HindIII fragment of pSVIR2-KH was cloned into the KpnI and
HindIII sites of pSVSPORT1 (GIBCO-BRL) to generate pSVIR2-H2. Fifty-
ﬁve bp oligonucleotide (5-tga cta ggt agc gca aat ttc aca ata aag caa tag
cat ctc tag acc caa gct t-3′) was cloned into the PvuII and HindIII sites
of pSVIR2-H2 to generate pSVIR2(1–706). To generate plasmid
pSVIR2(1–977), the 2.1-kb AscI–XbaI fragment of pSVIE(1–1299)
was cloned into the AscI and XbaI sites of pSVIR2-RX (see pREP4
plasmids below). pSVSPORT1 was digested with HindIII and EcoRI, a
synthetic linker B (coding strand: 5′-aat tGc cat ggc cca gct gac tct cga
ggaattc cta-3′, noncoding strand: 5′-agc tta ggaattc ctcg aga gtc agc tgg
gcc atg gc-3′) which contains an EcoRI sequence (underlined) was
inserted, and the plasmid was designated pSVSPORT-L of which the
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lacks the EcoRI consensus sequence at the end of the linker B (see the
capital letter; aattG). The 1.2-kb PvuII–XhoI fragment of pSVIR2-RX
was cloned into the PvuII and XhoI sites of Psvsport-L to generate
plasmid pSVIR2(707–1116). To generate plasmid pSVIR2(707-1116)
NH, a synthetic linker NLS-HA (coding strand: 5′-aa ttc ccg ccc gcc cct
aag cgg cgc gtg tac gac gta cca gat tac gct tac aaa ttt cac aaa taa agc aat
cta gac ca-3′, noncoding strand: 5′-agc ttg gtc tag att gct tta ttt gtg aaa
ttt cta agc gta atc tgg tac gtc gta cac gcg cct ctt agg ggc ggg cgg g-3′)
which contains nucleotide sequences for the IEP (IR2P) nuclear
localization signal (NLS) and hemagglutinin (HA) epitope tag was
cloned into the EcoRI and HindIII sites of pSVIR2(707–1116). To
generate plasmid pSVIR2(1–313)NH, the 950-bp IR2 DNA fragment
from pSVIR2 was ampliﬁed by PCR with primers (forward primer: 5′-
ccc ggt acc cac gcc atg gct tct ccg ccg ggc cgg agc cct cac-3′, reverse
primer: 5′-ggg gaa ttcg ggc ccg agg gcc gcg cag acc cgg gtg ta-3′) which
contain KpnI and EcoRI sites, respectively, and the fragment was
cloned into the KpnI and EcoRI sites of the pSVIR2(707–1165)NH
which contains nucleotide sequences for the IEP NLS and HA epitope
tag. To generate plasmid pSVIR2(1–313)(707–1165)NH, the 1230-bp
IR2 DNA fragment from pSVIR2 was ampliﬁed by PCR with primers
(forward primer: 5′-ggg gaa ttc ctg ttc ccc gag gcc tgg cgc ccg gcg ctc
acc ttc-3′, reverse primer: 5′-ccc aag ctt tca cac gcg cct ctt agg ggc ggg
cgg ctc gtc gtc ggg ctc cgg cag gca-3′) which contain EcoRI and HindIII
sites, respectively, and the fragment was cloned into the EcoRI and
HindIII sites of the pSVIR2(1-313)NH. To generate plasmid pSVIR2m1
(pSVIR2W171S), pSVIEW493S (1–1487) was digested with StuI and a
KpnI linker (5′-CCGGTACCGG-3′) was inserted. To generate
plasmid pSVIR2m2 (pSVIR2Q173E), and pSVIEQ495E(1–1487) was
digested with StuI and a KpnI linker (5′-CCGGTACCGG-3′) was
inserted. To generate plasmid pSVIR2m3 (pSVIR2N174I), pSVIEN496I
(1–1487)was digestedwith StuI and a KpnI linker (5′-cggtaccg-3′) was
inserted. To generate plasmid pSVIR2m4 (pSVIR2K176E), pSVIEK498E
(1–1487)was digestedwith StuI and a KpnI linker (5′-cggtaccg-3′) was
inserted. To generate plasmid pSVIR2(78–293)-NH, the 650-bp IR2
DNA fragment from pSVIR2 was ampliﬁed by PCR with primers
(forward primer: 5′-ccg gta cca gga tgg ctt cgt gcg ccc cgg gcg tct acc agc
gcg agc cg-3′, reverse primer: 5′-ccg aat tcg gcc tcg ggc tgt tgc tgg ctg
gcc gcg gc-3′) which contain KpnI and EcoRI sites, respectively, and the
fragment was cloned into the KpnI and EcoRI sites of the pSVSPORT1
and the plasmid was designated pSVIR2(78–293). A synthetic linker
NLS-HAwhich contains nucleotide sequences for the IEP (IR2P) nuclear
localization signal (NLS) and hemagglutinin (HA) epitope tag was
cloned into the EcoRI and HindIII sites of pSVIR2(78–293) to generate
plasmid pSVIR2(78–293)-NH. To generate plasmid pSVIR2(78–313)-
NH, the 700-bp IR2 DNA fragment from pSVIR2 was ampliﬁed by PCR
with primers (forward primer: 5′-ccg gta cca gga tgg cttc gtg cgc ccc ggg
cgt cta cca gcg cga gcc g-3′, reverse primer: 5′-ccg aat tcg ggc ccg agg gcc
gcg cag acc cgg gtg ta-3′) which contain KpnI and EcoRI sites,
respectively, and the fragment was cloned into the KpnI and EcoRI
sites of the pSVIR2(78–293)-NH. To generate plasmid pSVIR2(78–333)-
NH, the 760-bp IR2 DNA fragment from pSVIR2 was ampliﬁed by PCR
with primers (forward primer: 5′-ccg gta cca gga tgg ctt cgt gcg ccc cgg
gcg tct acc agc gcg agc cg-3′, reverse primer: 5′-ccg aat cgg cgg acg gcc
tgg gcg ccc tgg tcc ccg g-3′) which contain KpnI and EcoRI sites,
respectively, and the fragment was cloned into the KpnI and EcoRI sites
of the pSVIR2(78–293)-NH. To generate plasmid pSVIR2(78–397)-
NH, the 960-bp IR2 DNA fragment from pSVIR2 was ampliﬁed by
PCR with primers (forward primer: 5′-ccg gta cca gga tgg ctt cgt
gcg ccc cgg gcg tct acc agc gcg agc cg-3′, reverse primer: 5′-ccg aat
tcc agc ccg gcc ggg ttg gcg cac agc gcc tc-3′) which contain KpnI and
EcoRI sites, respectively, and the fragment was cloned into the
KpnI and EcoRI sites of the pSVIR2(78–293)-NH. To generate
plasmid pSVIR2(78–438)-NH, the 1080-bp IR2 DNA fragment from
pSVIR2 was ampliﬁed by PCR with primers (forward primer: 5′-ccg
gta cca gga tgg ctt cgt gcg ccc cgg gcg tct acc agc gcg agc cg-3′,reverse primer: 5′-ccg aat tca acg gcg cgc acc gcg agg cgc agc tcg tc-
3′) which contain KpnI and EcoRI sites, respectively, and the
fragment was cloned into the KpnI and EcoRI sites of the pSVIR2
(78–293)-NH.
pREP4 plasmids
IR2P-expressing Vero cell lines were generated by using the pREP4
vector system (Invitrogen, San Diego, CA). To generate plasmid pREP-
IR2(1–1116), the 3.9-kb HindIII–EcoRI fragment of pSVIR2 was cloned
into the HindIII and EcoRI sites of pcDNAI/Amp (Invitrogen), and the
plasmid was designated pC-IR2. The 3.5-kb KpnI–XhoI fragment of
pC-IR2 was cloned into the KpnI and XhoI sites of pREP4 to generate
pREP-IR2(1–1116). To generate plasmid pREP-IR2(1–1165), the 0.5-
kb XhoI fragment of pC-IR2 was cloned into the XhoI site of pREP-IR2
(1–1116). To generate plasmid pREP-IR2(1–1165)-N, 24 bp synthetic
oligonucleotide (5′-aagctcctctagagcccaagcttcgaattc-3′) was cloned
into the HindIII and EcoRI sites of pSVIR2-KH, and the plasmid was
designated pSVIR2-RX. The 3.9-kb KpnI–HindIII fragment of pSVIR2-
RX was cloned into the KpnI and HindIII sites of pREP4 to generated
pREP-IR2(1–1165)-N. To generate plasmid pREP-IR2(1–800), the
300-bp IR2 DNA fragment from pSVIR2 was ampliﬁed by PCR with
primers (forward primer: 5′-ctc atc gac aac cag ctg ttc ccc gag gcc-3′,
reverse primer: 5′-cca agc ttg ggt cta gat gct att gct tta ttt gtg aaa ttt
gcg cta cct agg acc aga ggg gct cgc gcc gag agc cgc c-3′) which contain
PvuII and HindIII sites, respectively, and the fragment was cloned into
the PvuII and HindIII sites of the pREP-IR2(1–1165)-N. To generate
plasmids pREP-IR2(1–706), the 2.2-kb KpnI–XhoI fragment of pSVIR2
(1–706) was cloned into the KpnI and XhoI sites of pREP4
(Invitrogen). To generate plasmid pREP-IR2Δ707/900, the 840-bp
IR2 DNA fragment from pSVIR2 was ampliﬁed by PCR with primers
(forward primer: 5′-ccc agc tga ctc cgc ggg tcg cct gcg ccg tgc gc-3′,
reverse primer: 5′-tgc cgg cct cga gcg gcc gct agc aag ctt-3′) which
contain PvuII and HindIII sites, respectively, and the fragment was
cloned into the PvuII and HindIII sites of the pREP-IR2(1–1165)-N. To
generate plasmid pREP-IR2(707–1116)NH, the 1.2-kb KpnI–HindIII
fragment of pSVIR2(707–1116)NH was cloned into the KpnI and
HindIII sites of pREP4.
GST fusion, luciferase reporter, and the secreted alkaline phosphatase
(SEAP) plasmids
Plasmids pGST-IR2, pGSTKG-TFIIB, pGST-hTBP, pIE-Luc, pEICP0-
Luc, pIR4 (EICP22)-Luc, pUL5 (EICP27)-Luc have been described
previously (Jang et al., 2001; Kim et al., 2006). Plasmid pICP22-SEAP
(kindly provided by S. V. Hsia, University of Maryland Eastern Shore)
has been described previously (Bedadala et al., 2007). To generate
plasmid pGST-IR2W493S, the 4.0-kb StuI–EcoRI fragment of
pSVIEW493S(1–1487) was cloned into the SmaI and EcoRI sites of
pGEX-KG (Guan and Dixon, 1991). To generate plasmid pGST-
IR2Q495E, the 4.0-kb StuI–EcoRI fragment of pSVIEQ495E(1–1487)
was cloned into the SmaI and EcoRI sites of pGEX-KG. To generate
plasmid pGST-IR2N496I, the 4.0-kb StuI–EcoRI fragment of
pSVIEN496I(1–1487) was cloned into the SmaI and EcoRI sites of
pGEX-KG. To generate plasmid pGST-IR2K498E, the 4.0-kb StuI–EcoRI
fragment of pSVIEK498E(1–1487) was cloned into the SmaI and EcoRI
sites of pGEX-KG.
Expression and puriﬁcation of GST fusion proteins
The expression and puriﬁcation of GST-fusion proteins has been
described elsewhere (Kim et al., 1995). The bacterial strains
Escherichia coli BL21 (DE3)pLysE (Novagen, Madison, WI) was
employed for induction of GST-fusion protein synthesis. The methods
for desalting and for ascertaining the concentration of the puriﬁed
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Jang et al., 2001).
In vitro transcription/translation reactions
In vitro transcription/translation (IVTT) reactions were performed
with the TNT SP6 High Yield Wheat Germ Master Mix (Promega,
Madison, WI) according to the manufacturer's directions. 35S-labeled
proteins were synthesized by including [35S]methionine (40 μCi/ml;
speciﬁc activity, 1175 Ci/mmol; New England Nuclear Corporation,
Boston, MA) in the IVTT reactions. Synthesis of the 35S-labeled
proteins was veriﬁed by SDS-PAGE analysis and autoradiography.
GST-pulldown assays
GST-pulldown assays that employed 35S-labeled polypeptides
were performed as detailed previously (Kim et al., 2003). Brieﬂy,
2 μg of either GST alone or the indicated GST fusion protein were
mixed with 35S-labeled proteins in 700 μl of NETN buffer. The 35S-
labeled proteins precipitated by the GST fusion protein were analyzed
by SDS-PAGE followed by autoradiography and visualization using the
Storm phosphorImager (Molecular Dynamics) or the Molecular
Imager FX system (Bio-Rad Laboratories, Hercules, CA).
Gel shift assays
The IE promoter region (position −16 to +22) was end-labeled
with [γ-32P]ATP as previously detailed (Kim et al., 1995). DNA-
binding assays were conducted as previously described (Kim et al.,
1995). The standard DNA-binding reaction mixture contained 0.5 to
1 ng of radiolabeled DNA fragments (2×104cpm/ng), 0.1 μg of poly
(dI–dC) as a nonspeciﬁc competitor, and 1 to 10 μl of puriﬁed proteins
in 20 μl of DNA-binding buffer (20 mM Hepes–KOH [pH 7.9], 0.5 mM
dithiothreitol, 10% glycerol, 0.1 mM EDTA, 0.025% NP-40, 25 mM KCl,
2 mM MgCl2). After 20 min at 22 °C, 5 μl of loading buffer (200 mM
Hepes-KOH [pH 7.5], 50% (vol/vol) glycerol, 0.02% bromophenol blue)
was added, and the sample was subjected to electrophoresis at 22 °C
for 2 h at 200 V on a 3% polyacrylamide gel with 0.5× Tris-Borate-
EDTA running buffer.
Luciferase reporter assays
The luciferase reporter assay was performed as previously
described (Kim et al., 2006). Brieﬂy, L-M cells were seeded at 50%
conﬂuency in 24 well plates, and transfected with 0.12 pmol of
reporter vector and 0.08 pmol of effectors. Six microliter of lipofectin
(Invitrogen) was mixed with 300 μl of Opti-MEM medium and
incubated for 45 min at room temperature. The effector and reporter
vectors were mixed with 300 μl of Opti-MEM medium, and the total
amount of DNA was adjusted to the same amount with pSVSPORT1
DNA. The solutions were combined and incubated at room temper-
ature for 15 min, and one-third volume was transferred into each of
three wells of L-M cells. After a further 5 h, the cells were re-fed with
fresh medium. At 40 h posttransfection, luciferase activity was
measured by using a luciferase assay kit (Promega, Madison, WI)
and a Polarstar Optima plate reader (BMG LABTECH Inc., Cary, NC).
The secreted alkaline phosphatase (SEAP) assays
SEAP activity in culture medium was determined by a chemilu-
minescence method using a Great Escape SEAP kits (Clontech, Palo
Alto, CA). In brief, 10-μL samples were mixed with 30 μl of dilution
buffer and incubated at 65 °C for 30 min. Forty microliters of assay
buffer containing L-homoarginine was then added. After 5 min at
room temperature, the samples were exposed to 40 μl of chemilumi-
nescent substrate CSPD (disodium 3-[4-methoxyspiro{1.2-dioxetane-3,2′-(5′-chloro)tricyclo(3.3.1.1)-decan}4-yl]phenyl phosphate)
(1.25 mM) or 3 μl of ﬂuorescent substrate 4-methylumbelliferyl
phosphate (Clontech). Chemiluminescence was measured with a
Polarstar Optima plate reader after a 20 min incubation at room
temperature.
Generation of anti-IEP trans-activation domain (TAD) polyclonal
antibody
Antibody generation has been described elsewhere (Ahn et al.,
2007; Charvat et al., in press). Brieﬂy, four New ZealandWhite rabbits
(approximately 3 kg per rabbit) were each immunized intramuscu-
larly in a hind leg with 500 μg of either puriﬁed GST-IEP TAD (aa1–88)
fusion protein (OC88 and OC89). The primary inoculum was
emulsiﬁed in Freund's complete adjuvant, and after 4–8 weeks,
booster immunizations emulsiﬁed in incomplete Freund's adjuvant
were administered every 14 days for a total of four booster injections
for each rabbit. Before each booster injection, small quantities of
serum were drawn from each rabbit to test antibody titers before the
ﬁnal bleed was performed. The anti-IEP TAD antibodies were puriﬁed
using protein A agarose beads (Pierce, Rockford, IL) according to the
manufacturer's directions. The working dilution in Western blot
assays was 1:6000 or greater (see Supplementary Fig. 3).
Western blot analysis
Preparation of cytoplasmic and nuclear extracts of transfected cells
and Western blot analysis were performed as previously described
(Kim et al., 2006). Blots were incubated with an anti-IE pAb OC33 for
1 h. The blots were washed three times for 10 min each in TBST and
incubated with secondary antibody (anti-rabbit IgG [Fc]-alkaline
phosphatase [AP] conjugate [Promega]) for 1 h. Proteins were
visualized by incubating the membranes containing blotted protein
in AP conjugate substrate (AP conjugate substrate kit, Bio-Rad)
according to manufacturer's directions.
Generation of IR2P-expressing Vero cell lines
Plasmid pREP4 is an episomal mammalian expression vector that
uses the Rous sarcoma virus long terminal repeat (RSV LTR) enhancer/
promoter for transcription of recombinant genes inserted into the
multiple cloning site. The Epstein–Barr Virus replication origin (oriP)
and nuclear antigen (encoded by the EBNA-1 gene) are carried by this
plasmid to permit extrachromosomal replication in human, primate,
and canine cells. pREP4 also carries the hygromycin B resistance gene
for stable selection in transfected cells. IR2P- and IEP-expressing Vero
cell lines were generated by using the pREP4 vector system
(Invitrogen) according to the manufacturer's instructions. Vero cells
were transfected with seven recombinant pREP4 plasmids [pREP-IR2
(1–1165), pREP-IR2(1–1116), pREP-IR2(1–800), pREP-IR2(1–706),
pREP-IR2Δ707/900, pREP-IR2(707–1116)NH, and PREP-IE] and
pREP4 control plasmid (Fig. 3A). Twenty-four hours after transfection,
the cells were washed and re-fed with fresh medium. At 48 h after
transfection, the cells were split into fresh medium containing
hygromycin B (Invitrogen) at 250 μg/ml and plated at a 25%
conﬂuence. The cells were fed with selective medium every 3 days
until hygromycin-resistant foci could be identiﬁed. Colonies were
picked and expanded in 48-well plates. These cell lines were selected
by IF and Western blot analyses and were maintained in medium
containing 50 μg/ml hygromycin.
Vero cell line viability assays
IR2P- and IEP-expressing Vero cell lines were infected with EHV-1
KyA at the indicated multiplicity of infection (MOI) and assayed for
cytopathic effect (CPE) and virus titer at 72 h postinfection (hpi).
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ﬂuorescence microscope. Cell viability was measured by CellTiter AQ
One solution (Promega). 2×104 Vero cells expressing full-length IR2P
or portions of IR2P were added to the wells of a 96-well plate. After
24 h incubation at 37 °C in a 5% CO2 atmosphere, assays were
performed by adding 20 μl of CellTiter 96 AQ one solution reagent
directly to culture 96 wells, and after incubation for 1 h the
absorbance at 490 nm was determined with a 96-well plate reader.
The cell culture media were harvested at 2, 24, 48, and 72 hpi, and
virus titers were determined by plaque assay on RK-13 cells. After
viability assays of the Vero cell lines were carried out, the Vero cells
were ﬁxed with 10% formalin solution (Fisher Scientiﬁc, Kalamazoo,
MI) and stained with crystal violet.
Plaque assays
Intracellular and extracellular EHV-1 virus titers were determined
on RK-13 cells. To prepare intracellular virus, infected cell monolayers
were rinsed 3× with fresh medium, scraped into 3 ml (the same
volume of the original medium), and subjected to three freeze–thaw
cycles. Serial dilutions of samples from each passage were used to
inoculate fresh RK-13 (EHV-1)monolayers. Infectedmonolayers were
incubated in medium containing 1.5% methylcellulose. Plaques were
quantitated after 2–4 days by ﬁxing with 10% formalin solution
(Fisher Scientiﬁc) and staining with 0.5% crystal violet.
Quantitative PCR
Vero cells and IR2P- or IEP-expressing Vero cell lines were infected
with EHV-1 at an MOI of 5. Cells were harvested at 24 hpi, and total
DNA was extracted from infected cell using DNeasy blood and tissue
Mini kit (QIAGEN, Valencia, CA). Quantitative PCR (qPCR) was
performed using the IQ™ 5multicolor real-time PCR detection system
with iQ SYBR green supermix according to the instructions of the
manufacturer (Bio-Rad, Hercules, CA). The comparative CT method for
relative quantitation (2−ΔΔCT) was used with human glyceralde-
hydes-3-phosphate dehydrogenase (GAPDH) as the endogenous
housekeeping gene. The primers used in qPCR were as follows:
GAPDH-F (5′-gggtttatggaggtcctcttgtgt-3′) and GAPDH-R (5′-
acccagtcctcccggtgacattta-3′) for GAPDH, UIE-F (5′-ctccgaggcccgcttc-
gacctagc-3′) and UIE-R (5′-agcagaggcggaaaagatgttgag-3′) for EHV-1
genomic DNA, REP-F (5′-ggcgaaaagcggggcttcggttgt-3′) and REP-R (5′-
cgtaccaccttacttccaccaatc-3′) for pREP4. Each sample was assayed in
triplicate.
RT-PCR
Total RNA was prepared using RNeasy Mini kit (QIAGEN, CA). One
step SYBR green real-time RT-PCR ampliﬁcation was carried out with
IQTM multicolor real-time PCR detection system with iScript one step
RT-PCR kit using SYBR Green according to the instructions of the
manufacturer (Bio-Rad, CA). RT conditions were as follows: 10 min at
50 °C and 5 min at 95 °C, followed by 40 cycles of PCR for 20 s at 95 °C
for denaturation, 60 s at 60 °C for annealing and extension. For the
melting curve analysis: After 40 reaction cycles, the temperature ramp
was programmed from 55 to 95 °C in increments of 0.5 °C, waiting
10 s before each acquisition. The primers used in RT-PCR were as
follows: IE RT-F (5′-atctccatctcatcgtcgtcctcgt-3′) and IE RT-R (5′-
ttcgtcgctgtcgctgtcgt-3′) for IE. EICP0 RT-F (5′-tctgctacgtgtgtat-
tacgcgct-3′) and EICP0 RT-R (5′-gtcaaagtccacgctcacctttgt-3′) for
EICP0. IR4 RT-F (5′-agagcagcgtttcggagtttagc-3′) and IR4 RT-R (5′-
ttcgctgctagaccactttccagt-3′) for IR4. UL5 RT-F (5′-agcccatggaggac-
gaaatgagta-3′) and UL5 RT-R (5′-aacaacactctttggtgggttgcc-3′) for UL5.
ETIF RT-F (5′-caagtttaaacaggtggtgcgcga-3′) and ETIF RT-R (5′-tgaagc-
gagacgaacacaccttga-3′) for ETIF. GAPDH-F (5′-acatcaagaaggtggtgaag-
cagg-3′) and GAPDH-R (5′-acaaagtggtcgttgagggcaatg-3′) for humanGAPDH. GAPDH-m-F (5′-atcactgccactcagaagactgt-3′) and GAPDH-m-
R (5′-accagtggatgcagggatgatgtt-3′) for mouse GAPDH. luc-F (5′-
aattctttatgccggtgttgggcg-3′) and luc-R (5′-gctgcgaaatgcccatactgttga-
3′) for ﬁreﬂy luciferase. Each sample was assayed in triplicate.
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